Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
United Therapeutics (DE:UTH)
FRANKFURT:UTH
United Therapeutics (UTH) Stock Price & Analysis
2 Followers
UTH Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€190.05 - €246.50
Previous Close€245.3
Volume15.00
Average Volume (3M)25.00
Market Cap
€10.89B
Enterprise Value€8.76B
Total Cash (Recent Filing)$2.99B
Total Debt (Recent Filing)$700.00M
Price to Earnings (P/E)N/A
Beta0.35
Next Earnings
Jul 31, 2024EPS Estimate
€5.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding44,355,694
10 Day Avg. Volume5
30 Day Avg. Volume25
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.00
Price to Sales (P/S)17.70
Price to Cash Flow (P/CF)19.50
P/FCF Ratio35.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.76
Enterprise Value/Gross Profit4.23
Enterprise Value/Ebitda6.45
Forecast
1Y Price Target
€280.48Price Target Upside14.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
United Therapeutics News
PremiumCompany Announcements
United Therapeutics Announces $1 Billion Stock Buyback Plan
Bulls Say, Bears Say
Bulls Say
Financial HealthUnited Therapeutics' strong balance sheet, with approximately $5 billion in cash and cash equivalents, showcases the company's robust financial health.
Product DemandWith Tyvaso being the most prescribed prostacyclin in the US, its dominant market position is expected to drive continued demand and financial growth.
Strategic InitiativesUnited Therapeutics' announcement of a $1 billion accelerated share repurchase program signals management's confidence in the company's value proposition and strategic vision.
Bears Say
Clinical Trial DelaysThe Phase 3 ADVANCE OUTCOMES trial for ralinepag is now expected to conclude in 2026, a delay due to slower accrual of clinical worsening events.
Increasing CompetitionCompetitive pressures exist with the launch of Merck's Winrevair, a novel activin signaling inhibitor for PAH treatment.
Legal And Regulatory ChallengesThe company is engaged in a legal dispute with the FDA, which creates uncertainty around the marketing of a competitor's product.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
8.71% Other Institutional Investors
91.29% Public Companies and
Individual Investors
UTH FAQ
What was United Therapeutics’s price range in the past 12 months?
United Therapeutics lowest stock price was €190.05 and its highest was €246.50 in the past 12 months.
What is United Therapeutics’s market cap?
Currently, no data Available
When is United Therapeutics’s upcoming earnings report date?
United Therapeutics’s upcoming earnings report date is Jul 31, 2024 which is in 78 days.
How were United Therapeutics’s earnings last quarter?
United Therapeutics released its earnings results on May 01, 2024. The company reported €5.743 earnings per share for the quarter, beating the consensus estimate of €5.312 by €0.432.
Is United Therapeutics overvalued?
According to Wall Street analysts United Therapeutics’s price is currently Undervalued.
Does United Therapeutics pay dividends?
United Therapeutics does not currently pay dividends.
What is United Therapeutics’s EPS estimate?
United Therapeutics’s EPS estimate is €5.91.
How many shares outstanding does United Therapeutics have?
Currently, no data Available
What happened to United Therapeutics’s price movement after its last earnings report?
United Therapeutics reported an EPS of €5.743 in its last earnings report, beating expectations of €5.312. Following the earnings report the stock price went down -0.809%.
Which hedge fund is a major shareholder of United Therapeutics?
Among the largest hedge funds holding United Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds United Therapeutics’s shares valued at 105M.
---
United Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€280.48 (14.86% Upside)
€280.48 (14.86% Upside)
Blogger Sentiment
Bullish
DE:UTH Sentiment 88%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $6.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.51%
12-Months-Change
Fundamentals
Return on Equity
20.08%
Trailing 12-Months
Asset Growth
2.35%
Trailing 12-Months
Company Description
United Therapeutics
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
---
UTH Company Deck
---
UTH Earnings Call
Q1 2024
0:00 / 0:00
---
UTH Revenue Breakdown
53.01% Tyvaso
21.26% Remodulin
15.44% Orenitram
8.55% Unituxin
1.75% Other
---
UTH Stock 12 Month Forecast
Average Price Target
€280.48
▲(14.86% Upside)
Technical Analysis
United Therapeutics
―
BioMarin Pharmaceutical
―
Catalyst Pharma
―
Heron Therapeutics
―
Incyte
―
Best Analysts Covering UTH
1 Year
1 Year Success Rate
24/28 ratings generated profit
1 Year Average Return
+19.96%
reiterated a buy rating 4 months ago
Copying Eun Yang's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +19.96% per trade.
---